z-logo
open-access-imgOpen Access
Pan-ebolavirus serology study of healthcare workers in the Mbandaka Health Region, Democratic Republic of the Congo
Author(s) -
Kelly Shaffer,
Sean Hui,
Anna Bratcher,
Liam B. King,
Rachel Mutombe,
Nathalie Kavira,
Jean Paul Kompany,
Merly Tambu,
Kamy Musene,
Patrick Mukadi,
Placide Mbala,
Adva Gadoth,
Brandyn R. West,
Benoît Kebela Ilunga,
Didine Kaba,
Jean Jacques Muyembe-Tanfum,
Nicole A. Hoff,
Anne W. Rimoin,
Erica Ollmann Saphire
Publication year - 2022
Publication title -
plos neglected tropical diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.99
H-Index - 135
eISSN - 1935-2735
pISSN - 1935-2727
DOI - 10.1371/journal.pntd.0010167
Subject(s) - ebolavirus , ebola virus , virology , medicine , immunology , serology , antibody , virus
Although multiple antigenically distinct ebolavirus species can cause human disease, previous serosurveys focused on only Zaire ebolavirus (EBOV). Thus, the extent of reactivity or exposure to other ebolaviruses, and which sociodemographic factors are linked to this seroreactivity, are unclear. We conducted a serosurvey of 539 healthcare workers (HCW) in Mbandaka, Democratic Republic of the Congo, using ELISA-based analysis of serum IgG against EBOV, Sudan ebolavirus (SUDV) and Bundibugyo ebolavirus (BDBV) glycoproteins (GP). We compared seroreactivity to risk factors for viral exposure using univariate and multivariable logistic regression. Seroreactivity against different GPs ranged from 2.2–4.6%. Samples from six individuals reacted to all three species of ebolavirus and 27 samples showed a species-specific IgG response. We find that community health volunteers are more likely to be seroreactive against each antigen than nurses, and in general, that HCWs with indirect patient contact have higher anti-EBOV GP IgG levels than those with direct contact. Seroreactivity against ebolavirus GP may be associated with positions that offer less occupational training and access to PPE. Those individuals with broadly reactive responses may have had multiple ebolavirus exposures or developed cross-reactive antibodies. In contrast, those individuals with species-specific BDBV or SUDV GP seroreactivity may have been exposed to an ebolavirus not previously known to circulate in the region.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here